IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Colorectal cancers that display reduced sensitivity to EGFR inhibition and strong IGF2 overexpression can be effectively treated by dual EGFR/IGF2 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, preclinical studies have shown that IGF2 overexpression attenuates the efficacy of cetuximab in CRC patient-derived xenografts (PDXs) [176].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [176]
The cited source says what the claim attributes to it.
In the citing paper
“This is supported by our observation, consolidated after monitoring hundreds of mCRC PDXs exposed to cetuximab (10, 25, 27, 29, 30), that complete responses are exceptional events.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [25]
In the citing paper
“Previous work from our group has shown that the effect of cetuximab in mCRC patient-derived models is cytostatic rather than cytotoxic (10, 25).”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [25]
In the citing paper
“Preclinical evidence has shown that mCRC PDXs captured at the moment of maximum shrinkage during cetuximab administration have massive reduction of cancer cell proliferation but do not display signs of apoptosis (10, 25).”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“Response to cetuximab in “quadruple negative” mCRC xenopatients: A population study in 125 cases Clinical studies have recently demonstrated that, in addition to the validated KRAS mutations in exon 2, additional KRAS mutations in exons 3 and 4, as well as NRAS, BRAF, and concurrent PIK3CA (exon 20) mutations, predict…”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
Cited by
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Self-citationInterrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.140 · Cited by 657
Self-citationGenetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
“Cancer-associated fibroblasts (CAFs) Fibroblasts that reside in the tumor microenvironment.”
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Self-citationInsulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Schütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Preclinical mouse solid tumour models: status quo, challenges and perspectives
Gengenbacher, N., Singhal, M., & Augustin, H. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.92 · Cited by 332
Isella, C., Brundu, F., Bellomo, S. E., Galimi, F., Zanella, E., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 302
Self-citationSartore-Bianchi, A., Lonardi, S., Martino, C., Fenocchio, E., Tosi, F., Ghezzi, S., Leone, F., Bergamo, F., Zagonel, V., Ciardiello, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000911 · Cited by 185
Self-citationErratum: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.24 · Cited by 183
Self-citationSimpson, A., Petnga, W., Macaulay, V. M., Weyer-Czernilofsky, U., & Bogenrieder, T. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0514-5 · Cited by 183
Wang, Y., Wei, Y., Bailey, C., Zhang, P., Zhang, P., Cheng, K., Raufman, J., Wang, Y., & Liu, Y. (2026) · Oncogene · doi:10.1038/s41388-026-03738-4 · Cited by 183
Biomarkers in colorectal cancer: Current clinical utility and future perspectives
Vacante, M., Borzì, A. M., Basile, F., & Biondi, A. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i15.869 · Cited by 170
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 165
Self-citationPonsioen, B., Post, J. B., Amorie, J. R. B. D., Laskaris, D., van Ineveld, R. L., Kersten, S., Bertotti, A., Sassi, F. P., Sipieter, F., Cappe, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00654-5 · Cited by 164
Self-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Chatila, W. K., Kim, J. K., Walch, H., Marco, M. R., Chen, C.-T., Wu, F., Omer, D. M., Khalil, D. N., Ganesh, K., Qu, X., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01930-z · Cited by 156
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 107
Leto, S. M., Sassi, F., Catalano, I., Torri, V., Migliardi, G., Zanella, E. R., Throsby, M., Bertotti, A., & Trusolino, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3066 · Cited by 104
Self-citationColorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation
Fessler, E., & Medema, J. P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.008 · Cited by 92
Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms
Unger, C., Kramer, N., Unterleuthner, D., Scherzer, M., Burian, A., Rudisch, A., Stadler, M., Schlederer, M., Lenhardt, D., Riedl, A., et al. (2017) · Oncogene · doi:10.1038/onc.2017.116 · Cited by 92
Kasprzak, A., & Adamek, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194915 · Cited by 87
Lupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8313 · Cited by 83
Self-citationRix, L. L. R., Sumi, N. J., Hu, Q., Desai, B., Bryant, A. T., Li, X., Welsh, E. A., Fang, B., Kinose, F., Kuenzi, B. M., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abj5879 · Cited by 82
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review
Brown, K. M., Xue, A., Mittal, A., Samra, J. S., Smith, R. C., & Hugh, T. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11184 · Cited by 77
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
Self-citationGarcía-Huerta, P., Troncoso-Escudero, P., Wu, D., Thiruvalluvan, A., Cisternas-Olmedo, M., Henríquez, D. R., Plate, L., Chaná‐Cuevas, P., Saquel, C., Thielen, P., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02183-1 · Cited by 72
Macaulay, V. M., Middleton, M. R., Eckhardt, S., Rudin, C. M., Juergens, R. A., Gedrich, R. W., Gogov, S., McCarthy, S. P., Poondru, S., Stephens, A. W., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2218 · Cited by 70
Druliner, B. R., Wang, P., Bae, T., Baheti, S., Slettedahl, S. W., Mahoney, D. W., Vasmatzis, N., Xu, H., Kim, M., Bockol, M. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21525-4 · Cited by 60
Chen, L., Liu, H.-Y., Xiao, Z., Qiu, T., Zhang, D., Zhang, L.-J., Han, F., Chen, G.-J., Xu, X.-M., Zhu, J.-H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06099-y · Cited by 59
Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Gelfo, V., Rodia, M. T., Pucci, M., Dall’Ora, M., Santi, S., Solmi, R., Roth, L. E., Lindzen, M., Bonafè, M., Bertotti, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12354 · Cited by 56
Self-citationCan luteolin be a therapeutic molecule for both colon cancer and diabetes?
Ambasta, R. K., Gupta, R. V., Kumar, D., Bhattacharya, S. K., Sarkar, A., & Kumar, P. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely036 · Cited by 52
Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51
Self-citationLee, J. S., Kang, J.-H., Boo, H., Hwang, S.-J., Hong, S., Lee, S.-C., Park, Y.-J., Chung, T.-M., Youn, H., Lee, S. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9499 · Cited by 51
Zhang, J., Chen, B., Li, H., Wang, Y., Liu, X., Wong, K. Y., Chan, W. N., Chan, A. K., Cheung, A. H. K., Leung, K. T., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6033 · Cited by 50
Jeevanandam, J., Tan, K. X., Danquah, M. K., Guo, H., & Turgeson, A. (2020) · Biotechnology Journal · doi:10.1002/biot.201900368 · Cited by 47
Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy
Turano, M., Delrio, P., Rega, D., Cammarota, F., Polverino, A., Duraturo, F., Izzo, P., & Rosa, M. D. (2019) · Cancers · doi:10.3390/cancers11121932 · Cited by 46
Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice
Chen, A., Neuwirth, I., & Herndler‐Brandstetter, D. (2023) · Cancers · doi:10.3390/cancers15112989 · Cited by 46
Molecular pathways: sensitivity and resistance to anti-EGFR antibodies
Bertotti, A., & Sassi, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0848 · Cited by 45
“001 by Fisher exact test), but not among those that are fully resistant to treatment (25).”
BackgroundInfluentialSelf-citationInoue, A., Deem, A. K., Kopetz, S., Heffernan, T. P., Draetta, G. F., & Carugo, A. (2019) · Cancers · doi:10.3390/cancers11091321 · Cited by 45
Capturing colorectal cancer inter‐tumor heterogeneity in patient‐derived xenograft (PDX) models
Prasetyanti, P. R., van Hooff, S. R., van Herwaarden, T., de Vries, N., Kalloe, K., Rodermond, H., van Leersum, R., de Jong, J. H., Franitza, M., Nürnberg, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31767 · Cited by 43
Zhu, X., Tian, X., Ji, L., Zhang, X., Cao, Y., Shen, C., Hu, Y., Wong, J. W. H., Fang, J.-Y., Hong, J., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00142-x · Cited by 41
Sepúlveda, D., Grünenwald, F., Vidal, A., Troncoso-Escudero, P., Cisternas-Olmedo, M., Villagra, R., Vergara, P., Aguilera, C., Nassif, M., & Vidal, R. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-05941-1 · Cited by 41
Beekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., Migliardi, G., Viviani, M., Grassi, E., Lupo, B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3687 · Cited by 39
Self-citationPan, Y., Jiao, L., Lin, C., Lu, C., Li, L., Chen, H., Wang, Y., & He, Y. (2018) · Biologics · doi:10.2147/btt.s166867 · Cited by 39
The changing paradigm of tumour response to irradiation
Hill, R. P. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160474 · Cited by 38
Zhong, H., Fazenbaker, C. A., Chen, C., Breen, S., Huang, J., Yao, X., Ren, P., Yao, Y., Herbst, R., & Hollingsworth, R. E. (2016) · Oncogene · doi:10.1038/onc.2016.248 · Cited by 38
Advances in Modeling the Immune Microenvironment of Colorectal Cancer
Yoon, P., Piccolo, N. D., Shirure, V. S., Peng, Y., Kirane, A., Canter, R. J., Fields, R. C., George, S. C., & Gholami, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.614300 · Cited by 35
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 35
Cordo’, V., Meijer, M. T., Hagelaar, R., Haas, R. R. D. G., Poort, V. M., Henneman, A. A., Piersma, S. R., Pham, T. V., Oshima, K., Ferrando, A. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28682-1 · Cited by 35
Sanderson, M. P., Hofmann, M. H., Garin‐Chesa, P., Schweifer, N., Wernitznig, A., Fischer, S., Jeschko, A., Meyer, R., Moll, J., Pecina, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0336 · Cited by 33
Tashiro, T., Okuyama, H., Endo, H., Kawada, K., Ashida, Y., Ohue, M., Sakai, Y., & Inoue, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174151 · Cited by 33
The GH-EXIN neural network for hierarchical clustering
Cirrincione, G., Ciravegna, G., Barbiero, P., Randazzo, V., & Pasero, E. G. A. (2019) · Neural Networks · doi:10.1016/j.neunet.2019.07.018 · Cited by 33
Dang, Q., Zuo, L., Hu, X., Zhou, Z., Chen, S., Liu, S., Ba, Y., Zuo, A., Xu, H., Weng, S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70041 · Cited by 32
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
Yang, J., Li, S., Wang, B., Wu, Y., Chen, Z., Lv, M., Lin, Y., & Yang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5140-9 · Cited by 32
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
Self-citationMin, H.-Y., Lee, S.-C., Woo, J. K., Jung, H. J., Park, K. H., Jeong, H. M., Hyun, S. Y., Cho, J., Lee, W., Park, J. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0534 · Cited by 30
Luraghi, P., Bigatto, V., Cipriano, É., Reato, G., Orzan, F., Sassi, F. P., Bacco, F. D., Isella, C., Bellomo, S. E., Médico, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2151 · Cited by 29
Self-citationJacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1831 · Cited by 27
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts
Corso, S., Cargnelutti, M., Durando, S., Menegon, S., Apicella, M., Migliore, C., Capelôa, T., Ughetto, S., Isella, C., Médico, E., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.003 · Cited by 27
Self-citationFeedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
Bosch-Vilaró, A., Jacobs, B., Pomella, V., Asbagh, L. A., Kirkland, R. E., Michel, J., Singh, S., Liu, X., Kim, P., Weitsman, G. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13834 · Cited by 26
Self-citationRational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Self-citationBrijwani, N., Jain, M., Dhandapani, M., Zahed, F., Mukhopadhyay, P., Biswas, M., Khatri, D., Radhakrishna, V. D., Majumder, B., Radhakrishnan, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01566-x · Cited by 24
Leto, S. M., Grassi, E., Avolio, M., Vurchio, V., Cottino, F., Ferri, M., Zanella, E. R., Borgato, S., Corti, G., di Blasio, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51909-2 · Cited by 24
Self-citationPatient‐derived xenograft model in colorectal cancer basic and translational research
Liu, X., Xin, Z., & Wang, K. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12299 · Cited by 24
Shao, M., Jiang, L., Meng, Z., & Xu, J. (2022) · Molecules · doi:10.3390/molecules27041404 · Cited by 23
Sanderson, M. P., Apgar, J. F., Garin‐Chesa, P., Hofmann, M. H., Kessler, D., Quant, J., Savchenko, A., Schaaf, O., Treu, M., Tye, H., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0539 · Cited by 21
O’Farrell, A. C., Jarzabek, M. A., Lindner, A. U., Carberry, S., Conroy, E., Miller, I. S., Connor, K., Shiels, L., Zanella, E. R., Lucantoni, F., et al. (2020) · Cancers · doi:10.3390/cancers12102978 · Cited by 20
Self-citationGao, T., Liu, X., He, B., Pan, Y., & Wang, S. (2020) · Aging · doi:10.18632/aging.103837 · Cited by 19
Kjær, I., Lindsted, T., Fröhlich, C., Olsen, J. V., Horak, I. D., Kragh, M., & Pedersen, M. W. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0565 · Cited by 19
Mouse models in the era of large human tumour sequencing studies
de Ruiter, J. R., Wessels, L. F. A., & Jonkers, J. (2018) · Open Biology · doi:10.1098/rsob.180080 · Cited by 18
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00926-7 · Cited by 17
Ye, P., Qu, C., & Hu, X.-L. (2015) · Tumor Biology · doi:10.1007/s13277-015-4489-5 · Cited by 17
Marín‐Vicente, C., Mendes, M. L., Ríos, V. D. L., Fernández‐Aceñero, M. J., & Casal, J. I. (2019) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201900052 · Cited by 14
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Cui, Y., Chen, Y., & Liu, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01829-8 · Cited by 12
Lindner, A. U., Carberry, S., Monsefi, N., Barat, A., Salvucci, M., O’Byrne, R., Zanella, E. R., Cremona, M., Hennessy, B. T., Bertotti, A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33226 · Cited by 12
Self-citationThe Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy
Catalano, I., & Trusolino, L. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.001 · Cited by 12
Self-citationCONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system
Pernice, S., Sirovich, R., Grassi, E., Viviani, M., Ferri, M., Sassi, F. P., Alessandrì, L., Tortarolo, D., Calogero, R., Trusolino, L., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad201 · Cited by 11
Self-citationInsulin receptor alternative splicing in breast and prostate cancer
Li, J., & Huang, G. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03252-1 · Cited by 11
Clinical and genomic characteristics of metabolic syndrome in colorectal cancer
Li, Y., Zhao, J., Wu, X., Zhang, Y., Jin, Y., & Cai, W. (2021) · Aging · doi:10.18632/aging.202474 · Cited by 10
First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients
Moiseyenko, V. M., Moiseenko, F. V., Yanus, G. A., Kuligina, E. S., Соколенко, А. П., Валерьевич, Б. И., Кудрявцев, А. А., Алексахина, С. Н., Volkov, N., Chubenko, V. A., et al. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0629-1 · Cited by 10
Han, X., Hou, S., & Yang, A. (2016) · Medical Science Monitor · doi:10.12659/msm.895837 · Cited by 9
Avolio, M., Leto, S. M., Sassi, F. P., Lupo, B., Grassi, E., Catalano, I., Zanella, E. R., Vurchio, V., Cottino, F., Tsantoulis, P. K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0556 · Cited by 9
Self-citationNeural Biclustering in Gene Expression Analysis
Barbiero, P., Ciravegna, G., Piccolo, E., Cirrincione, G., Cirrincione, M., & Bertotti, A. (2017) · International Conference on Computational Science and Computational Intelligence (CSCI) · doi:10.1109/csci.2017.361 · Cited by 8
Self-citationTao, B., Yi, C., Zhang, B., Geng, Y., Gu, Y., Sun, R., Wang, X., Lin, J., & Chen, J. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0972 · Cited by 8
Caracterización de los pacientes con cáncer de colon
Guibert Adolfo, L. A., Quiroga Meriño, L. E., Brizuela, Y. E., Ramos, O. M. M., & León, G. G. (2018) · Revista Archivo Médico de Camagüey · Cited by 8
Candiello, E., Reato, G., Verginelli, F., Gambardella, G., D′Ambrosio, A., Calandra, N., Orzan, F., Iuliano, A., Albano, R., Sassi, F. P., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13408 · Cited by 7
Self-citationUnsupervised Gene Identification in Colorectal Cancer
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Pasero, E. G. A., & Piccolo, E. (2018) · Smart innovation, systems and technologies · doi:10.1007/978-3-319-95095-2_21 · Cited by 7
Self-citationFontana, E., Nyamundanda, G., Cunningham, D., Tu, D., Cheang, M. C. U., Jonker, D. J., Siu, L. L., Sclafani, F., Eason, K., Ragulan, C., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00050 · Cited by 7
Self-citationFischer, A. D., Veronese-Paniagua, D., Swaminathan, S., Kashima, H., Rubin, D. C., & Madison, B. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00058.2022 · Cited by 7
Experimental toolkit to study the oncogenic role of WNT signaling in colorectal cancer
Dash, P., Yadav, V. K., Das, B., & Satapathy, S. R. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189354 · Cited by 5
Keri, R. A., Distelhorst, C., Sharifi, N., & Berger, N. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00031-6 · Cited by 3
Resistance to EGFR Targeting Treatments in Colorectal Cancer
Pucci, M., & Lauriola, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00018-1 · Cited by 3
Supervised Gene Identification in Colorectal Cancer
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Pasero, E. G. A., & Piccolo, E. (2018) · Smart innovation, systems and technologies · doi:10.1007/978-3-319-95095-2_23 · Cited by 3
Self-citationUnderstanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Piccolo, E., & Tonda, A. P. (2019) · Smart innovation, systems and technologies · doi:10.1007/978-981-13-8950-4_26 · Cited by 2
Self-citationResistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2
Self-citationDNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., & Piccolo, E. (2019) · Smart innovation, systems and technologies · doi:10.1007/978-981-13-8950-4_28 · Cited by 2
Self-citationMOLECULAR MARKERS OF SENSITIVITY AND RESISTANCE OF COLORECTAL CANCER TO ANTI-EGFR THERAPY
Ivantsov, A. O., Yanus, G. A., Suspitsin, E. N., Anisimova, E. I., & Imyanitov, E. N. (2016) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2016-15-1-59-66 · Cited by 2
Metadata
- Authors
- Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., Medico, E., Tejpar, S., Budinská, E., Trusolino, L., & Bertotti, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Department of Oncology, University of Torino Medical School, 10060 Candiolo, Torino, Italy.
- Universitair Ziekenhuis Leuven (BE)
- Institute of Biostatistics and Analyses, Masaryk University, 611 37 Brno, Czech Republic.
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Corresponding author
- Zanella, Eugenia R.
- Galimi, Francesco
- Sassi, Francesco
- Trusolino, Livio
- Bertotti, Andrea
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-01-28
- Volume
- 7
- Issue
- 272
- Pages
- 272ra12-272ra12
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2144987077
- Cited by
- 117
- References
- 47
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 5 · 2023: 10 · 2022: 9 · 2021: 14 · 2020: 13 · 2019: 12 · 2018: 13 · 2017: 14 · 2016: 13 · 2015: 7
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- American Association for Cancer Research (12-20-16-BERT)
- Ministero dell'Universita e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- AIRC Investigator (14205, 11852)
- European Regional Development Fund
- Fondo per gli Investimenti della Ricerca di Base_Futuro in Ricercaq
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS
- State Budget of the Czech Republic-RECAMO (CZ.1.05/2.1.00/03.0101)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin-like growth factor II, colorectal cancer, anti-EGFR therapy, cetuximab, stable disease, patient-derived xenografts, IGF2 overexpression, combination therapy, predictive biomarkers, treatment resistance
- MeSH terms
- Cetuximab, Animals, Antineoplastic Agents, Clinical Trials as Topic, Exons, Humans, Immunohistochemistry, Insulin-Like Growth Factor II, Ligands, Mutation, Neoplasm Transplantation, Biomarkers, Tumor, Colorectal Neoplasms, Drug Resistance, Neoplasm, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.